June 2026 · 8 min read · Clinical Protocol
What Is Frozen Shoulder (Adhesive Capsulitis)?
Frozen shoulder — medically termed adhesive capsulitis — is a progressive fibrotic condition of the glenohumeral joint capsule characterized by painful restriction of active and passive shoulder range of motion in all planes. It affects 2–5% of the general population and up to 22% of people with diabetes mellitus, making it a high-prevalence condition in the Philippines where an estimated 7–8 million Filipinos live with type 2 diabetes.
The condition evolves across three clinically distinct stages. Without effective intervention, the natural course spans 18–36 months, during which patients typically cannot raise their arm above shoulder level, struggle with basic daily activities (dressing, reaching overhead, sleep positioning), and often face significant occupational impairment. The BPO and office workforce — a key Philippine demographic — is particularly affected due to prolonged desk postures and high stress-related cortisol levels that predispose to fibrotic shoulder conditions.
The Three Stages of Frozen Shoulder
Understanding stage-specific treatment is essential for effective management:
Stage 1: Freezing (1–9 months)
Characterized by insidious-onset severe shoulder pain, particularly at night, with progressive restriction of movement. Histologically: synovial hyperplasia, vascular proliferation, and early capsular fibrosis. Pain is the dominant symptom. This is the most responsive stage for PEMF anti-inflammatory intervention — early treatment here can truncate progression to subsequent stages.
Stage 2: Frozen (9–15 months)
Pain begins to decrease but stiffness becomes severe and disabling. The anterior capsule, coracohumeral ligament, and rotator interval are densely fibrotic. Range of motion (ROM) reaches its minimum: external rotation typically limited to <30°, flexion to <90°, abduction to <60°. PEMF in this stage targets the fibrotic capsule, combined with gentle mobilization.
Stage 3: Thawing (15–36 months)
Gradual spontaneous resolution of stiffness with improving function. PEMF + physiotherapy during this stage accelerates the resolution, potentially compressing 18+ months of recovery into 6–8 months of structured treatment.
How PEMF Addresses Frozen Shoulder Biology
Three validated mechanisms explain PEMF's efficacy in adhesive capsulitis:
- Suppression of synovial fibroblast activity: Activated fibroblasts are the primary drivers of capsular thickening and contracture. PEMF at 25–50 Hz downregulates TGF-β1-driven fibroblast proliferation and collagen deposition, interrupting the fibrotic cascade at its source.
- Anti-inflammatory cytokine modulation: The inflammatory mediators IL-1β, IL-6, and TNF-α drive synovial hyperplasia in Stage 1. PEMF consistently suppresses these cytokines in periarticular tissue, reducing the inflammatory driver of capsular fibrosis.
- Periarticular microcirculation improvement: Reduced blood flow and hypoxia in the shoulder capsule perpetuate the fibrotic process. PEMF stimulates local angiogenesis and microcirculation, restoring oxygen delivery to the ischemic capsular tissue and supporting resolution of contracture.
Clinical Evidence for PEMF in Adhesive Capsulitis
A 2024 systematic review (PMC10898218) examined PEMF and electromagnetic stimulation modalities in shoulder conditions, concluding that pulsed electromagnetic therapy produces statistically significant improvements in pain VAS scores and shoulder ROM compared to sham treatment across multiple RCT designs. The review identified consistent benefits in both Stage 1 (pain-dominant) and Stage 2 (stiffness-dominant) presentations.
Additionally, the PEMF efficacy data from the broader musculoskeletal evidence base — PMC11914662 (n=91, 36% pain reduction vs. 10%, p<0.0001; 55% medication reduction) and PMC12088032 (shoulder-specific meta-analysis demonstrating VAS improvements of −2.6 points and DASH functional score improvements from 45.2 to 21.8) — support the biological plausibility and clinical magnitude of effect in this patient population.
The Stage-Specific PEMF Protocol
| Stage | Primary Goal | Frequency | Intensity | Duration | Sessions |
|---|---|---|---|---|---|
| Stage 1 (Freezing) | Anti-inflammatory, pain relief | 25–50 Hz | 10–20 mT | 30 min | 2–3×/week × 6 wks |
| Stage 2 (Frozen) | Capsular anti-fibrotic, ROM | 10–25 Hz | 15–30 mT | 35–40 min | 2×/week × 8 wks |
| Stage 3 (Thawing) | Accelerate resolution, function | 50–75 Hz | 10–20 mT | 30 min | 1–2×/week × 8 wks |
| Maintenance | Consolidation, recurrence prevention | 25–50 Hz | 10–15 mT | 25–30 min | 1×/month |
Combination Protocol: PEMF + Manual Therapy
The optimal clinical approach combines PEMF with graded shoulder mobilization. Sequence matters: PEMF is administered first (30–40 minutes), then the physiotherapist or osteopath performs passive stretching and joint mobilization. This ordering is mechanistically important — PEMF reduces capsular inflammation and pain sensitivity before manual therapy, enabling the therapist to achieve greater capsular stretch with lower patient discomfort.
- PEMF first: 30–40 minutes, shoulder coil centered on glenohumeral joint
- Manual therapy second: Maitland Grade III–IV glides, inferior and posterior capsular stretching, pendulum exercises
- Home program: Codman pendulum exercises and cross-body stretches between sessions
This combined approach — used across 70+ Israeli clinics (population: 9M) now expanding to the Philippines — consistently reduces recovery time from the typical 18–36-month natural course to 6–12 months of active treatment.
PEMF vs. Standard Treatment Approaches
| Treatment | Mechanism | Evidence Level | Best Stage | Adverse Effects | Philippines Cost |
|---|---|---|---|---|---|
| PEMF | Anti-fibrotic, anti-inflammatory, microcirculation | RCT evidence (PMC10898218) | All stages | Very rare | ₱1,500–₱2,500/session |
| Corticosteroid injection | Non-specific anti-inflammatory | Level 1 (short-term) | Stage 1 (early) | Infection, tendon weakening | ₱3,000–₱8,000/injection |
| Physiotherapy alone | ROM restoration | Level 1 | Stages 2–3 | Pain during exercise | ₱800–₱1,500/session |
| Hydrodilatation | Capsular distension | Level 2 | Stage 2 | Pain, capsule tear risk | ₱8,000–₱20,000 |
| MUA (Manipulation Under Anaesthesia) | Forced capsular release | Level 3 | Stage 2 (refractory) | Fracture, neurovascular injury | ₱30,000–₱80,000 |
| Arthroscopic release | Surgical capsular division | Level 2 | Refractory (any stage) | Surgical risk, infection | ₱80,000–₱200,000+ |
Who Is This Treatment For?
PEMF is appropriate for all stages of frozen shoulder and all patient profiles, including diabetic patients (who are most susceptible), post-thyroid surgery patients, post-cardiac surgery patients (left shoulder at risk), and those with bilateral involvement. Contraindications are narrow: active pacemaker, pregnancy, active epilepsy, or active malignancy in the treatment area. No additional contraindications specific to frozen shoulder apply.
The patient profile most likely to complete a full PEMF course: working-age adults (30–65) with significant functional impairment affecting their occupation, who are seeking to avoid surgery or repeated injections. This demographic has reliable disposable income and strong motivation to complete treatment — the highest-retention patient segment for clinic revenue planning.
The Clinic Investment Case
Frozen shoulder patients require extended treatment courses (20–30 sessions across 3–6 months) with high completion rates due to strong functional motivation. At ₱1,500–₱2,500/session, a single patient represents ₱30,000–₱75,000 in total revenue. A clinic running 3–4 frozen shoulder patients per day generates ₱90,000–₱300,000 monthly from this indication alone — before accounting for other conditions.
Interested in how frozen shoulder and related shoulder conditions fit into your Philippine clinic's revenue model? Request the full investment and implementation brief.
Request Investment Brief →Frequently Asked Questions
How quickly does pain improve with PEMF for frozen shoulder?
Most Stage 1 patients (freezing phase) report meaningful pain reduction after 3–6 sessions. Stage 2 patients (frozen) typically see stiffness improvement after 6–10 sessions, with ROM gains becoming measurable at 4–6 weeks of twice-weekly treatment. Stage 3 patients generally experience the fastest functional gains.
Can PEMF replace physiotherapy for frozen shoulder?
PEMF is most effective as an adjunct to manual therapy and exercise, not a replacement. The evidence consistently shows better outcomes when PEMF reduces pain and inflammation before physiotherapy — enabling more effective capsular stretching with less discomfort. The combination is the clinical standard in evidence-based practice.
How does frozen shoulder differ from rotator cuff injury?
Frozen shoulder (adhesive capsulitis) involves capsular fibrosis — the joint capsule itself thickens and contracts. Rotator cuff injuries involve the tendon complex surrounding the joint. Both cause shoulder pain but have different pathologies and PEMF protocols. Frozen shoulder characteristically restricts passive ROM in all planes; rotator cuff injuries typically limit active more than passive movement.
Are there contraindications for PEMF in frozen shoulder?
Standard PEMF contraindications apply: implanted cardiac devices (pacemakers, ICDs), pregnancy, active epilepsy, active malignancy in the shoulder region. Titanium implants (shoulder replacements, anchors) are generally not a contraindication, but the treating clinician should confirm with the device manufacturer for each specific case.